美国Idera Pharmaceuticals
Idera Pharmaceuticals develops drug candidates to treat infectious diseases, autoimmune and inflammatory diseases, cancer, and respiratory diseases, and for use as vaccine adjuvants. Our proprietary drug candidates are designed to modulate specific Toll-like Receptors (TLRs), which are a family of immune system receptors that direct immune system responses. Our pioneering DNA and RNA chemistry expertise enables us to create drug candidates for our internal development programs and our partnered programs, and generates opportunities for additional collaborative alliances.

We have three drug candidates in clinical development and multiple preclinical stage programs:

IMO-2055 in clinical development for cancer treatment (licensee: Merck KGaA)
IMO-2125 in clinical development for hepatitis C virus infection
QAX935 (IMO-2134) in clinical development for asthma and allergies (licensee: Novartis)
IMO-3100 in IND-enabling preclinical development for autoimmune and inflammatory diseases
TLR7, 8 and 9 agonists for use as adjuvants in vaccines: (licensee: Merck & Co. Inc.)
TLR7 and TLR8 agonists in preclinical research for oncology and infectious diseases
TLR antisense in preclinical research for autoimmune and inflammatory diseases